Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9235) 9235
Publication (685) 685
Book Review (53) 53
Book Chapter (50) 50
Magazine Article (21) 21
Conference Proceeding (11) 11
Newsletter (10) 10
Dissertation (7) 7
Book / eBook (4) 4
Government Document (4) 4
Paper (2) 2
Reference (2) 2
Trade Publication Article (2) 2
Web Resource (2) 2
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (7248) 7248
male (3767) 3767
female (3455) 3455
myelofibrosis (3366) 3366
middle aged (3153) 3153
hematology (2983) 2983
aged (2644) 2644
index medicus (2566) 2566
adult (2228) 2228
primary myelofibrosis - pathology (1787) 1787
oncology (1589) 1589
primary myelofibrosis (1544) 1544
essential thrombocythemia (1483) 1483
polycythemia-vera (1448) 1448
primary myelofibrosis - complications (1401) 1401
mutation (1183) 1183
bone marrow - pathology (1048) 1048
primary myelofibrosis - diagnosis (1017) 1017
primary myelofibrosis - genetics (995) 995
janus kinase 2 - genetics (964) 964
myeloproliferative disorders (929) 929
primary myelofibrosis - drug therapy (898) 898
myeloid metaplasia (877) 877
aged, 80 and over (858) 858
myeloproliferative neoplasms (850) 850
leukemia (837) 837
prognosis (811) 811
polycythemia vera (751) 751
idiopathic myelofibrosis (713) 713
primary myelofibrosis - etiology (708) 708
primary myelofibrosis - blood (655) 655
primary myelofibrosis - therapy (621) 621
bone marrow (610) 610
animals (607) 607
myeloproliferative disorders - genetics (567) 567
adolescent (564) 564
jak2 (555) 555
diagnosis, differential (542) 542
tyrosine kinase jak2 (529) 529
treatment outcome (518) 518
pathology (516) 516
diagnosis (510) 510
biopsy (475) 475
ruxolitinib (451) 451
medicine, general & internal (441) 441
agnogenic myeloid metaplasia (426) 426
anemia (412) 412
splenectomy (401) 401
polycythemia vera - genetics (399) 399
retrospective studies (390) 390
disorders (389) 389
genetic aspects (385) 385
care and treatment (383) 383
risk factors (383) 383
survival (381) 381
tumors (378) 378
thrombocythemia, essential - genetics (374) 374
myeloproliferative disorders - pathology (371) 371
therapy (354) 354
abridged index medicus (347) 347
international working group (346) 346
hematopoiesis (344) 344
mice (341) 341
research (340) 340
follow-up studies (338) 338
medicine & public health (334) 334
primary myelofibrosis - mortality (331) 331
young adult (323) 323
primary myelofibrosis - metabolism (318) 318
fibrosis (315) 315
analysis (314) 314
myeloproliferative disorders - diagnosis (314) 314
child (313) 313
chronic disease (313) 313
chronic myeloproliferative disorders (313) 313
hemic and lymphatic diseases (310) 310
transplantation (308) 308
cancer (303) 303
polycythemia (291) 291
janus kinase 2 - antagonists & inhibitors (288) 288
stem cells (284) 284
hematology, oncology and palliative medicine (274) 274
janus kinase 2 (274) 274
acute disease (273) 273
disease (268) 268
polycythemia vera - pathology (268) 268
bone-marrow (266) 266
expression (266) 266
disease progression (265) 265
thrombosis (262) 262
polycythemia vera - complications (259) 259
splenomegaly (258) 258
spleen - pathology (257) 257
primary myelofibrosis - physiopathology (256) 256
neoplasms (252) 252
myelodysplastic syndromes (251) 251
cells (247) 247
classification (247) 247
megakaryocytes - pathology (247) 247
pyrazoles - therapeutic use (245) 245
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7660) 7660
German (340) 340
French (305) 305
Japanese (230) 230
Russian (155) 155
Spanish (151) 151
Italian (131) 131
Polish (68) 68
Chinese (56) 56
Hungarian (37) 37
Czech (36) 36
Korean (35) 35
Romanian (22) 22
Turkish (19) 19
Dutch (18) 18
Danish (12) 12
Swedish (12) 12
Portuguese (11) 11
Norwegian (5) 5
Serbian (5) 5
Slovak (5) 5
Bulgarian (4) 4
Croatian (4) 4
Hebrew (4) 4
Finnish (3) 3
Slovenian (2) 2
Afrikaans (1) 1
Bosnian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text A confusing “white cell count”: Circulating micromegakaryocytes in post‐thrombocythemia myelofibrosis
by Sale, Silvia and Rocco, Vincenzo and Pancione, Ylenia and Carri, Daniele Delli and Fumi, Maurizio and Bain, Barbara J
American Journal of Hematology, ISSN 0361-8609, 05/2019, Volume 94, Issue 5, pp. 617 - 618
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis
by Masarova, Lucia and Bose, Prithviraj and Daver, Naval and Pemmaraju, Naveen and Newberry, Kate J and Manshouri, Taghi and Cortes, Jorge and Kantarjian, Hagop M and Verstovsek, Srdan
Leukemia Research, ISSN 0145-2126, 2017, Volume 59, pp. 110 - 116
Highlights • Retrospective comparison of 1099 patients with primary and PET/PPV-MF myelofibrosis. • Patients with PET-MF have longer overall survival than... 
Hematology, Oncology and Palliative Medicine | polycythemia vera myelofibrosis | essential thrombocythemia myelofibrosis | Primary myelofibrosis | Prognosis | Post | SURVIVAL | DIAGNOSIS | RISK-FACTORS | PROGNOSTIC-FACTORS | COMPLICATION | CONSENSUS | Post polycythemia vera myelofibrosis | Post essential thrombocythemia myelofibrosis | EVOLUTION | ONCOLOGY | FREQUENCY | MUTATIONS | HEMATOLOGY | LIFE EXPECTANCY | Primary Myelofibrosis - mortality | Follow-Up Studies | Leukemia, Myeloid, Acute - pathology | Humans | Middle Aged | Male | Survival Rate | Thrombocythemia, Essential - pathology | Primary Myelofibrosis - pathology | Disease Progression | Young Adult | Aged, 80 and over | Adult | Female | Aged | Polycythemia Vera - pathology | Pets | Anemia | Polycythemia | Leukemia | post-essential thrombocythemia myelofibrosis | post-polycythemia vera myelofibrosis | primary myelofibrosis | prognosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text A dynamic prognostic model to predict survival in primary myelofibrosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
by Passamonti, Francesco and Cervantes, Francisco and Vannucchi, Alessandro Maria and Morra, Enrica and Rumi, Elisa and Pereira, Arturo and Guglielmelli, Paola and Pungolino, Ester and Caramella, Marianna and Maffioli, Margherita and Pascutto, Cristiana and Lazzarino, Mario and Cazzola, Mario and Tefferi, Ayalew
Blood, ISSN 0006-4971, 03/2010, Volume 115, Issue 9, pp. 1703 - 1708
Age older than 65 years, hemoglobin level lower than 100 g/L (10 g/dL), white blood cell count greater than 25 x 10(9)/L, peripheral blood blasts 1% or higher,... 
CYTOGENETIC ABNORMALITIES | DIAGNOSIS | IDIOPATHIC MYELOFIBROSIS | POST-POLYCYTHEMIA VERA | AGNOGENIC MYELOID METAPLASIA | DISORDERS | SCORING SYSTEM | STEM-CELL TRANSPLANTATION | ESSENTIAL THROMBOCYTHEMIA | HEMATOLOGY | WORLD-HEALTH-ORGANIZATION | Primary Myelofibrosis - mortality | Prognosis | Age Factors | Humans | Middle Aged | Risk Factors | Proportional Hazards Models | Hemoglobins - metabolism | Male | Models, Statistical | Primary Myelofibrosis - blood | Models, Biological | Female | Aged | Leukocyte Count | Primary Myelofibrosis - therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Guideline for the diagnosis and management of myelofibrosis
by Reilly, John T and McMullin, Mary Frances and Beer, Philip A and Butt, Nauman and Conneally, Eibhlean and Duncombe, Andrew and Green, Anthony R and Michaeel, N. George and Gilleece, Marie H and Hall, Georgina W and Knapper, Steven and Mead, Adam and Mesa, Ruben A and Sekhar, Mallika and Wilkins, Bridget and Harrison, Claire N and British Comm Standards Haematology and Writing group: British Committee for Standards in Haematology
British Journal of Haematology, ISSN 0007-1048, 08/2012, Volume 158, Issue 4, pp. 453 - 471
Summary The guideline group regarding the diagnosis and management of myelofibrosis was selected to be representative of UK‐based medical experts, together... 
treatment | myelofibrosis | myeloproliferative disorders | transplantation | Transplantation | Myelofibrosis | Treatment | Myeloproliferative disorders | PROGNOSTIC SCORING SYSTEM | CHRONIC IDIOPATHIC MYELOFIBROSIS | BONE-MARROW-TRANSPLANTATION | INTERNATIONAL-WORKING-GROUP | ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS | DONOR-LYMPHOCYTE INFUSION | INTRAHEPATIC PORTOSYSTEMIC SHUNT | AGNOGENIC MYELOID METAPLASIA | STEM-CELL TRANSPLANTATION | SINGLE-INSTITUTION EXPERIENCE | HEMATOLOGY | Evidence-Based Medicine - methods | Primary Myelofibrosis - diagnosis | Prognosis | Primary Myelofibrosis - complications | Humans | Immunosuppressive Agents - therapeutic use | Anemia - therapy | Bone Marrow Transplantation - methods | Enzyme Inhibitors - therapeutic use | Janus Kinases - antagonists & inhibitors | Splenectomy | Primary Myelofibrosis - genetics | Primary Myelofibrosis - therapy | Hematopoietic Stem Cell Transplantation - methods | Anemia - etiology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
by Naseema Gangat and Domenica Caramazza and Rakhee Vaidya and Geeta George and Kebede Begna and Susan Schwager and Daniel Van Dyke and Curtis Hanson and Wenting Wu and Animesh Pardanani and Francisco Cervantes and Francesco Passamonti and Ayalew Tefferi
Journal of Clinical Oncology, ISSN 0732-183X, 02/2011, Volume 29, Issue 4, pp. 392 - 397
Purpose The Dynamic International Prognostic Scoring System (DIPSS) for primary myelofibrosis (PMF) uses five risk factors to predict survival: age older than... 
CYTOGENETIC ABNORMALITIES | SURVIVAL | POLYCYTHEMIA-VERA | WORKING GROUP | NEOPLASMS | ONCOLOGY | LEUKEMIA | MUTATIONS | ESSENTIAL THROMBOCYTHEMIA | CLINICAL-RELEVANCE | INFERIOR | Blood Transfusion - mortality | Primary Myelofibrosis - mortality | Predictive Value of Tests | Leukemia - blood | Prognosis | Age Factors | Health Status Indicators | Humans | Middle Aged | Male | Primary Myelofibrosis - blood | Young Adult | Time Factors | Cell Transformation, Neoplastic - genetics | Karyotyping | Aged, 80 and over | Adult | Female | Leukocyte Count | Leukemia - genetics | Severity of Illness Index | Primary Myelofibrosis - diagnosis | Reproducibility of Results | Risk Assessment | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Leukemia - therapy | Chi-Square Distribution | Bone Marrow Examination | Databases as Topic | Disease-Free Survival | Primary Myelofibrosis - genetics | Platelet Count | Adolescent | Leukemia - diagnosis | Aged | Primary Myelofibrosis - therapy | Hemoglobins - analysis | Leukemia - mortality
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text What is pre‐fibrotic myelofibrosis and how should it be managed in 2018?
by Curto‐Garcia, Natalia and Ianotto, Jean‐Christophe and Harrison, Claire N
British Journal of Haematology, ISSN 0007-1048, 10/2018, Volume 183, Issue 1, pp. 23 - 34
Summary The 2016 World Health Organization (WHO) classification for myeloproliferative neoplasms (MPN) divided myelofibrosis (MF) into pre‐fibrotic (pre‐MF)... 
primary myelofibrosis | myeloproliferative neoplasm | classification | management | prefibrotic myelofibrosis | DIAGNOSIS | MYELOPROLIFERATIVE NEOPLASMS | RISK | ESSENTIAL THROMBOCYTHEMIA | INTERNATIONAL PROGNOSTIC SCORE | GUIDELINE | DISEASE | HEMATOLOGY | Primary Myelofibrosis - diagnosis | Prognosis | World Health Organization | Humans | Myeloproliferative Disorders - classification | Fibrosis | Primary Myelofibrosis - classification | Disease Management | Primary Myelofibrosis - therapy | Primary Myelofibrosis - pathology | Myelofibrosis | Young adults | Leukemia | Scoring | Lactate dehydrogenase | Management | Patients | Neoplasms | L-Lactate dehydrogenase | Medical prognosis | Classification | Bone marrow | Thrombocytosis | Adults | Diagnostic systems | Lactic acid | Diagnosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT)
by Mesa, Ruben A and Verstovsek, Srdan and Cervantes, Francisco and Barosi, Giovanni and Reilly, John T and Dupriez, Brigitte and Levine, Ross and Le Bousse-Kerdiles, Marie-Caroline and Wadleigh, Martha and Campbell, Peter J and Silver, Richard T and Vannucchi, Alessandro M and Deeg, H. Joachim and Gisslinger, Heinz and Thomas, Deborah and Odenike, Olatoyosi and Solberg, Lawrence A and Gotlib, Jason and Hexner, Elizabeth and Nimer, Stephen D and Kantarjian, Hagop and Orazi, Attilio and Vardiman, James W and Thiele, Juergen and Tefferi, Ayalew and International Working Group for Myelofibrosis Research and Treatment (IWG-MRT)
Leukemia Research, ISSN 0145-2126, 2007, Volume 31, Issue 6, pp. 737 - 740
Abstract The International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) is comprised of hematologists, hematopathologists, and laboratory... 
Hematology, Oncology and Palliative Medicine | IWG-MRT | Primary myelofibrosis | Myelofibrosis | Myelofibrosis with myeloid metaplasia | Chronic idiopathic myelofibrosis | International Working Group for Myelofibrosis Research and Treatment | Myeloproliferative disorders | Blast Crisis - classification | Blast Crisis - pathology | Thrombocythemia, Essential - classification | Humans | Polycythemia Vera - classification | Terminology as Topic | Primary Myelofibrosis - classification | Thrombocythemia, Essential - pathology | Primary Myelofibrosis - pathology | Cell Transformation, Neoplastic - classification | Polycythemia Vera - pathology | Cell Transformation, Neoplastic - pathology | Chronic Disease
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
by Ayalew Tefferi and Rakhee Vaidya and Domenica Caramazza and Christy Finke and Terra Lasho and Animesh Pardanani
Journal of Clinical Oncology, ISSN 0732-183X, 04/2011, Volume 29, Issue 10, pp. 1356 - 1363
Purpose Abnormal cytokine expression accompanies myelofibrosis and might be a therapeutic target for Janus-associated kinase (JAK) inhibitor drugs. This study... 
SOLUBLE INTERLEUKIN-2-RECEPTOR | GROWTH-FACTOR-BETA | JAK2 INHIBITOR | ONCOLOGY | ACUTE LYMPHOBLASTIC-LEUKEMIA | IDIOPATHIC MYELOFIBROSIS | CHRONIC LYMPHOCYTIC-LEUKEMIA | MYELOPROLIFERATIVE NEOPLASMS | MYELOID METAPLASIA | ANGIOGENIC FACTORS | BONE-MARROW FIBROSIS | Predictive Value of Tests | Up-Regulation | Prognosis | Humans | Middle Aged | Male | Primary Myelofibrosis - pathology | Case-Control Studies | Protein Array Analysis - methods | Primary Myelofibrosis - blood | Interleukin-12 - blood | Aged, 80 and over | Adult | Female | Cytogenetic Analysis | Interleukin-8 - blood | Enzyme-Linked Immunosorbent Assay | Risk Assessment | Primary Myelofibrosis - immunology | Receptors, Interleukin-2 - blood | Risk Factors | Janus Kinase 2 - genetics | Kaplan-Meier Estimate | Proportional Hazards Models | Genotype | Interleukin-15 - blood | Minnesota | Chi-Square Distribution | Bone Marrow Examination | Biomarkers, Tumor - blood | Phenotype | Primary Myelofibrosis - genetics | Biopsy | Aged | Mutation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: Clinical, cytogenetic and molecular comparisons
by Tefferi, A and Lasho, T.L and Finke, C.M and Knudson, R.A and Ketterling, R and Hanson, C.H and Maffioli, M and Caramazza, D and Passamonti, F and Pardanani, A
Leukemia, ISSN 0887-6924, 2014, Volume 28, Issue 7, pp. 1472 - 1477
Calreticulin (CALR) mutations were recently described in JAK2 and MPL unmutated primary myelofibrosis (PMF) and essential thrombocythemia. In the current... 
CALR | JAK2 | prognosis | myeloproliferative | survival | Primary Myelofibrosis - mortality | Primary Myelofibrosis - diagnosis | Gene Expression | Prognosis | Humans | Middle Aged | Janus Kinase 2 - genetics | Male | Calreticulin - genetics | Receptors, Thrombopoietin - genetics | Primary Myelofibrosis - genetics | DNA Mutational Analysis | Chromosome Aberrations | Aged, 80 and over | Female | Aged | Mutation | Myelofibrosis | Gene mutations | Oncology, Experimental | Genetic research | Genetic aspects | Research | Identification and classification | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text The international prognostic scoring system does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis
by Hernández-Boluda, Juan-Carlos and Pereira, Arturo and Gómez, Montse and Boqué, Concepción and Ferrer-Marín, Francisca and Raya, José-María and García-Gutiérrez, Valentín and Kerguelen, Ana and Xicoy, Blanca and Barba, Pere and Martínez, Jesús and Luño, Elisa and Alvarez-Larrán, Alberto and Martínez-López, Joaquín and Arbelo, Elisa and Besses, Carles and Grp Espanol Enfermedades Mieloprol and Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas and on behalf of the Grupo Espanol de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN)
Haematologica, ISSN 0390-6078, 2014, Volume 99, Issue 4, pp. e55 - e57
Post-ET myelofibrosis | Post-PV myelofibrosis | IPSS | Survival | Prognostic factors | post-ET myelofibrosis | survival | prognostic factors | post-PV myelofibrosis | MODEL | HEMATOLOGY | Primary Myelofibrosis - mortality | Polycythemia Vera - complications | Primary Myelofibrosis - diagnosis | Primary Myelofibrosis - drug therapy | Prognosis | Humans | Primary Myelofibrosis - etiology | Thrombocythemia, Essential - complications | Online Only
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Prefibrotic versus overtly fibrotic primary myelofibrosis: clinical, cytogenetic, molecular and prognostic comparisons
by Mudireddy, Mythri and Shah, Sahrish and Lasho, Terra and Barraco, Daniela and Hanson, Curtis A and Ketterling, Rhett P and Gangat, Naseema and Pardanani, Animesh and Tefferi, Ayalew
British Journal of Haematology, ISSN 0007-1048, 08/2018, Volume 182, Issue 4, pp. 594 - 597
prefibrotic PMF | reticulin fibrosis | primary myelofibrosis | distinction | prognosis | DIAGNOSIS | ESSENTIAL THROMBOCYTHEMIA | HEMATOLOGY | BONE-MARROW FIBROSIS | Primary Myelofibrosis - mortality | Disease-Free Survival | Primary Myelofibrosis - genetics | Humans | Middle Aged | Aged, 80 and over | Adult | Primary Myelofibrosis - classification | Survival Rate | Aged | Primary Myelofibrosis - metabolism | Myelofibrosis | Fibrosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
by Klampfl, Thorsten and Gisslinger, Heinz and Gisslinger, Bettina and Harutyunyan, Ashot S and Nivarthi, Harini and Rumi, Elisa and Milosevic, Jelena D and Them, Nicole C.C and Berg, Tiina and Pietra, Daniela and Chen, Doris and Vladimer, Gregory I and Bagienski, Klaudia and Milanesi, Chiara and Casetti, Ilaria Carola and Sant'Antonio, Emanuela and Ferretti, Virginia and Elena, Chiara and Schischlik, Fiorella and Cleary, Ciara and Six, Melanie and Schalling, Martin and Schönegger, Andreas and Bock, Christoph and Malcovati, Luca and Pascutto, Cristiana and Superti-Furga, Giulio and Cazzola, Mario and Kralovics, Robert
The New England Journal of Medicine, ISSN 0028-4793, 12/2013, Volume 369, Issue 25, pp. 2379 - 2390
The authors identified calreticulin mutations in the majority of patients with essential thrombocythemia and myelofibrosis who did not have JAK2 mutations. The... 
MEDICINE, GENERAL & INTERNAL | POLYCYTHEMIA-VERA | GAIN-OF-FUNCTION | DISORDERS | COMPETING RISKS | PRIMARY MYELOFIBROSIS | ESSENTIAL THROMBOCYTHEMIA | JAK2 | PROGNOSTIC MODEL | PREDICT SURVIVAL | INTERNATIONAL WORKING GROUP | Primary Myelofibrosis - mortality | Exons | Humans | Leukemia, Myeloid - genetics | Janus Kinase 2 - genetics | Proportional Hazards Models | Thrombocythemia, Essential - genetics | Calreticulin - genetics | Sequence Analysis, DNA | Bone Marrow Diseases - genetics | Receptors, Thrombopoietin - genetics | Primary Myelofibrosis - genetics | Thrombosis - etiology | Thrombocythemia, Essential - mortality | Polymerase Chain Reaction | Mutation | Thrombocythemia, Essential - complications | Antibody diversity | Research | Health aspects | Myeloproliferative disorders | Myelofibrosis | Transcription | Medical treatment | Genes | Polycythemia vera | Stat5 protein | Thrombosis | Blood | Thrombopoietin | Calreticulin | Clonal deletion | Polycythemia | Janus kinase 2 | Janus kinase
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights